Heart Health
Wegovy for Heart Health: A Clinically Approved Treatment for UK Patients
Wegovy is a prescription treatment that has been clinically studied in patients with cardiovascular disease who are overweight or obese. Clinical trials have shown a reduction in major adverse cardiovascular events, like heart attacks or strokes, in certain patient groups.
What is Wegovy?
This prescription weight-loss treatment is approved in the UK for adults living with overweight or obesity. It mimics a naturally occurring hormone in the body that regulates blood sugar, appetite, and metabolism. In addition to helping patients lose weight, it has been studied for its potential role in cardiovascular risk reduction in specific patient groups.
The cardiovascular benefits can include:- Reduced cardiovascular risk observed in clinical studies.
- Reductions in high blood pressure and diastolic blood pressure have been observed in some patients.
- Improvements in cardiovascular health markers, including high cholesterol and inflammatory markers associated with blood vessels.
- Weight management support, reducing the strain of excess weight on the heart
- Improved blood sugar regulation, supporting diabetes control in those with Type 2 diabetes
Obesity and Risk of Cardiovascular Disease
Being overweight can significantly increase your risk of heart attacks, strokes, and other serious cardiovascular conditions. Previously, weight-loss treatments focused on reducing body weight, but not heart protection.
Recent clinical studies have explored the relationship between weight management treatments and cardiovascular outcomes.
Cardiovascular disease is the leading cause of death in the UK¹.
A reduction in major cardiovascular events has been observed in clinical studies.
Results from the SELECT Clinical Trial:
Reduction in heart attack, stroke, or cardiovascular death
Participants
All patients had established heart disease and were overweight or obese
Cardiovascular benefits were seen without diabetes being present
The trial measured adverse cardiovascular events, including non-fatal strokes and other cardiovascular events
How Wegovy May Support Cardiovascular Health
Wegovy mimics a natural hormone in your body that:
- Helps regulate blood sugar and insulin, supporting improved diabetes control
- May support reductions in inflammation
- Supports weight loss, which is associated with improved cardiovascular health
- May contribute to improvements in blood pressure and cholesterol levels in some patients
Results from the SELECT Clinical Trial:
Reduction in heart attack, stroke, or cardiovascular death
Participants
All patients had established heart disease and were overweight or obese
Cardiovascular benefits were seen without diabetes being present
The trial measured adverse cardiovascular events, including non-fatal strokes and other cardiovascular events
How Wegovy May Support Cardiovascular Health
Wegovy mimics a natural hormone in your body that:
- Helps regulate blood sugar and insulin, supporting improved diabetes control
- May support reductions in inflammation
- Supports weight loss, which is associated with improved cardiovascular health
- May contribute to improvements in blood pressure and cholesterol levels in some patients
How Effective is Wegovy for Heart Health
The SELECT clinical trial is one of the largest cardiovascular trials of its kind. The study demonstrated that Wegovy reduced the risk of major cardiac events in certain patients.
Cardiovascular outcomes were observed regardless of the amount of weight patients lost, suggesting that the heart health benefits extend beyond modest weight loss. Research showed improvement in cardiovascular risk contributors, including diastolic blood pressure and markers of systemic inflammation.
Are You Eligible?
This prescription weight-loss treatment is currently licensed for:
- Adults with established cardiovascular disease (heart attack, stroke, PAD, or other established cardiovascular conditions)
- A body mass index (BMI) of 27 or higher (overweight or obese)
- No diabetes required (though it has been studied in patients with type 2 diabetes when appropriately managed)
Why Choose Envigore?
Clinical Oversight
You’ll be reviewed by a UK prescriber experienced in cardiovascular health and weight management.
Easy Ordering
Once approved, Wegovy is delivered straight to your door — discreetly and quickly. All prescriptions are dispensed through our GPhC-registered pharmacy partner, Right Medicine Pharmacy Group.
Ongoing Support
We offer lifestyle and medication guidance tailored for heart health and weight management. Our patients get access to ongoing support from our patient care team, available Monday to Friday via telephone, email and private patient forums.
Holistic Tools
From hypnotherapy to supplements, we provide support for both cardiovascular health and lifestyle changes. We understand that long-term change goes beyond medication alone, and we provide structured support alongside treatment.
Envigore provides specialist weight management services. Our support goes beyond prescriptions. We offer clinician-reviewed prescriptions with a range of complementary support services. In addition to prescription weight-loss medication, we offer:
2 out of 3
Adults in England are living with obesity or excess weight²
20%
Wegovy reduces risk of CV events in high-risk groups³
22 Million
Studies on people globally using GLP-1s⁴
39.8 Months
Benefits were seen over the period in SELECT trial³
References
- British Heart Foundation. Heart Statistics UK.
- NHS Digital. Health Survey for England 2025.
- SELECT Trial: NEJM. Marso SP et al. 2023
- Novo Nordisk Global Semaglutide Safety Data, 2024.
- FDA Press Release, March 2024.
FAQs
Frequently Asked Questions
Carrying excess weight places additional strain on the heart and blood vessels. This increases the risk of heart disease. Weight loss is known to improve heart health and reduce the risk of cardiovascular events such as heart attacks and strokes.
You do not need to have diabetes to be eligible. The SELECT trial demonstrated cardiovascular benefits in patients without diabetes. However, a diagnosis of established cardiovascular disease is part of the current licensed criteria for this indication. Eligibility is always confirmed during your clinical assessment.
A qualified healthcare professional must make any decision to combine treatments to review your full medical history. Wegovy has been studied in patients taking heart medication, including those for high blood pressure and high cholesterol.
About Your Clinical Team
This content was medically reviewed and approved by Danny Gian Hou Chu, a HCPC-Registered Physician Associate (PA38670), who oversees all prescribing decisions at Envigore.
All prescriptions are dispensed by Right Medicine Pharmacy, a GPhC-Registered Pharmacy (No. 9012382).
Nutritional guidance and lifestyle support is provided by Veronica Giudice, a HCPC-Registered Dietitian (DT26570) and British Dietetic Association member.
Last medically reviewed: April 2026